Fosamax Lawsuits Surpass 800 in Federal Fosamax Femur Fracture Litigation, Bernstein Liebhard LLP Reports

Share Article

The Firm is currently investigating Fosamax lawsuits on behalf of individuals who suffered femur fractures, allegedly due to their use of Fosamax.

Bernstein Liebhard LLP | Consumer Injury Lawyers
We continue to hear from Fosamax users who suffered debilitating femur fractures. We expect the number of Fosamax lawsuits involving these types of injuries will only continue to grow.

Court documents indicate that some 870 Fosamax lawsuits have now been filed in a federal multidistrict-litigation underway in U.S. District Court, District of New Jersey. The Fosamax litigation was established in May 2011 by the U.S. Judicial Panel on Multidistrict Litigation for all federal lawsuits sharing similar claims that long-term use of Fosamax caused plaintiffs to suffer femur fractures and similar bone injuries. (In re: Fosamax (alendronate sodium) Products Liability Litigation, MDL No. 2243, D. N.J.)

“We continue to hear from Fosamax users who suffered debilitating femur fractures. We expect the number of Fosamax lawsuits involving these types of injuries will only continue to grow,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of Fosamax femur fractures.

Fosamax Femur Fracture Lawsuits
Fosamax is an oral bisphosphonate used by millions of post-menopausal women to prevent fractures from osteoporosis. In October 2010, the U.S. Food & Drug Administration (FDA) added new information to the Fosamax label after studies linked bisphosphonates with an increased risk of atypical femur fractures. As the risk of Fosamax femur fractures appears to be associated with long-term use, the FDA has cautioned doctors to reevaluate bisphosphonate therapy in patients who have been taking the drugs for more than 5 years.*

In May 2012, an FDA-commissioned analysis published in the New England Journal of Medicine raised additional concerns about the long-term risks associated with drugs like Fosamax. Among other things, the study found that there was little benefit in taking bisphosphonates for longer than five years due to their association with atypical femur fractures and other side effects.**

In addition to the Fosamax litigation underway in New Jersey federal court, additional femur fracture claims are pending in a consolidated litigation established in New Jersey Superior Court, Atlantic County. (In re: Fosamax Litigation, No. 282, N.J. Super. Ct) Court documents indicate that the first Fosamax femur fracture claims will start going to trial this spring in both litigations.
Fosamax users who suffered femur fractures possibly associated with this medication could be entitled to compensation for their medical bills, lost wages and pain and suffering. A wealth of information regarding Fosamax lawsuits is available by visiting Bernstein Liebhard LLP’s website, To arrange for a free review of your Fosamax femur fracture lawsuit, please contact Bernstein Liebhard LLP at (877) 779-1414.


About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website